ReviewCrohn's & colitis 3602021

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics.

Remo PanaccionePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.